Evvy Raises $40M to Transform Women's Health Research with Vaginal Microbiome Data

Evvy Secures $40 Million to Expand Women's Health Platform

Women's health company Evvy announced it has raised $40 million in Series B funding led by Catalio Capital Management, with participation from new investors including the U.S. Fertility Innovation Fund, Rethink Impact, Muse Capital, and Alumni Ventures.1

1

2

2

Previous backers such as LabCorp Venture Fund, General Catalyst, and Left Lane Capital also joined the round. Founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, the AI-powered startup operates what it describes as the world's only at-home CLIA-certified and CLEP-certified mNGS test for analyzing the vaginal microbiome with a single swab.1

1

Addressing Critical Gaps in Precision Medicine for Women

Evvy is tackling a fundamental flaw in precision medicine: the severe lack of high-quality, representative data on female biology. "You can't build precision medicine for women on data sets that never adequately measured female biology in the first place," CEO Priyanka Jain explained.1

1

The problem stems from clinical trials excluding women until 1993, leaving only about 30 years of research data on female biology.2

2

This gap has resulted in misdiagnosis rates exceeding 50% for some conditions and recurrence rates above 60% for common vaginal symptoms.2

2

Women frequently hear terms like "unexplained infertility," "unexplained recurrence," or "unexplained pain"—labels that really mean medicine wasn't built to measure female biology properly.

Building the World's Largest Vaginal Microbiome Dataset

Since launch, Evvy has served more than 100,000 patients across the United States and works with 3,000 practitioners.1

1

The company has generated 15 peer-reviewed publications and abstracts, identified novel bacterial vaginosis subtypes, and discovered hundreds of previously uncatalogued vaginal microbiome genomes.1

1

Users mail their swab samples to Evvy's lab, which analyzes results using metagenomic sequencing, sends them to clinicians registered on its platform for review, and posts results in the patient's health portal with diagnosis, clinical interpretation, and personalized prescription care when relevant.1

1

EvvyAI Delivers Precision Diagnostics and Personalized Treatment

In May, Evvy launched EvvyAI, an AI assistant that translates vaginal microbiome data into real-time guidance for users and directs patients to clinicians for questions requiring expert opinions.1

1

Licensed clinicians using EvvyAI for precision diagnostics for women's health report successfully diagnosing more than 90% of symptomatic patients, leading to a 50% reduction in the recurrence of conditions like bacterial vaginosis.2

2

Through analysis of women's microbiomes, Evvy identified six distinct BV subtypes, enabling far more personalized treatment pathways for patients who appeared similar under traditional diagnostic criteria but had meaningfully different biomes, recurrence patterns, and responses to treatments.2

2

Expanding into Fertility Research and Beyond

Evvy is now entering the fertility space, its first major foray beyond vaginal health. The company is compiling data and science linking vaginal microbiomes to infertility, gynecological cancer, preterm birth, IVF success rates, and recurrent pregnancy loss.1

1

Last year, Evvy launched a prospective study leveraging its vaginal microbiome tests in IVF clinics.1

1

"Women shouldn't have to accept unexplained infertility, unexplained recurrence or unexplained symptoms as answers when what they often mean is that medicine hasn't caught up to the data yet," Jain said.1

1

The company's long-term vision includes creating a new-age Pap smear—an at-home, non-invasive sample providing women with regular, data-rich insights across infections, inflammation, fertility, PCOS, endometriosis, premenopause, HPV progression, and more.1

1